For years now Tim Holme has watched the same drama repeat itself roughly once a week. A headline arrives: some laboratory somewhere has cracked the problem, invented the battery of the future, solved ...
AI agents are not yet creative enough to carry out genuinely innovative open-ended AI research, it seems. The AI industry’s boldest promise right now is that AI will soon improve itself, with almost ...
Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...
I recommend a speculative buy on Factorial Energy Inc. due to attractive risk/reward at near-SPAC valuation despite high risk. FAC has achieved significant OEM validation, delivering high-density ...
Stellantis holds 9.5% stake in solid state battery startup Factorial, filing shows Automaker Stellantis holds a 9.5% stake in U.S. solid-state battery startup Factorial Energy and might ‌buy further ...
Factorial Energy has surged post-SPAC IPO, but its $3B valuation is driven by low float and retail-driven hype. FAC's technology is validated by major OEMs, but commercial contracts and revenue remain ...
Founded in the greater Boston area, Factorial develops solid-state batteries. Credit: Noah Emad / Shutterstock.com US solid-state battery developer Factorial Energy has begun trading on the Nasdaq ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company is backed by ...
Electric vehicle adoption has slowed in America, but battery demand remains high, boosted by energy storage, defense, and space applications. The Sixth U.S. Circuit Court of Appeals in Cincinnati ...
BARCELONA—Factorial closed a $150 million funding round that lifted its valuation to $2.5 billion, bringing in fresh capital to expand as artificial intelligence reshapes the business-management ...
Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...